Member Info for olderbutwiser

Exactly SuperStockMan

Feels like we are dredging the very bottom of the barrel now to find things to be affronted about.

Hi Soup
You say that you ' find odd is that all of the board members, Riddell, Brindley, Gilbert and Kennedy regularly post news on their linkedin pages, but... none of them has ever posted anything about Nuformix, lots about the other companies they work for, but not NFX?'
I was intrigued and so went onto Linkedin expecting to see loads of posts for all our directors - I selected 'All activity' and found next to nothing posted in the last year from any of them. Where are you seeing all these regular posts you mentioned?
AB had just one post 6 months ago congratulating a professor at Imperial College and nothing else within a year.
JG also had just one post 2 moths ago about the Oxitope Pharma launch and nothing else within the year.
AR also had just one post 1 month ago about Ubiquitent's extended relationship with BMS and nothing else within the year.
I am puzzled regarding your comments? lots about their other companies??

In the same interview on 17th November AR stated:
"We will be upping our activities in the business development field"
Seems to suggest that having concentrated on the science they are now moving onto extracting the licensing potential and the deals.

Soup
AB stated in her Proactive interview of 17th Nov (at 4.17 minutes in).
"We plan to start to talk to potential licensees now we have filed this patent application"

The company website really does need updating to reflect the recent news slow - it is well behind events.

Hi Soup
You are correct to pick me up on that wording.
Once the latest patent was filed they were able to approach multiple pharma interested in the improved $billion oncology drug - so it is my assumption that they are progressing this avenue as quickly as they can.
Happy to clarify.

For me NXP004 is of most interest initially.
It has potential interest from multiple pharma - the originator and competitors - and therefore an element of competition which could well drive us to an earlier and potentially better deal.
Discussions are currently underway.
There could be a MOU or something even more tangible before AB leaves.
LA

The AGM response item 20 was simply their response to comments raised about the previous management and their over-optimistic statements and videos by DG during late 2019 and early 2020 and that they will operate in a fundamentally different and more cautious way than the last management. They clearly state that they are saying nowt till something is actually signed - on any talks – Asian or otherwise.

“the current management will only publicly comment on deals once they are fully signed and delivered, as is the appropriate approach for a listed company."

FFS
Toxicology must be tested as part of the pre-clinical suite of tests. As with any testing there is a potential risk – but Anne obviously knows a lot more than any of us and her comments taken from the recent RNS show reasonable confidence.
‘Dr Anne Brindley, CEO of Nuformix, said: "We're delighted with the positive readout of this data so far and it further cements our belief in NXP002 as a valuable asset. Tranilast is poorly soluble, meaning it is not well absorbed into the body and tissues, and it also has issues regarding systemic toxicity. NXP002 is a new form of tranilast that shows greater solubility than the original drug, allowing it to be delivered to the lungs that are the site of action for IPF. By delivering directly to the lungs, we anticipate that a lower dose will be required to produce a pharmacological and therapeutic effect with reduced systemic toxicity compared to oral dosing.’

Morning FFS - yes it was odd not to mention the combination tests carried out last year.Earlier in the interview AR said "So the work we are going to do to make this phase 1 ready will be formal toxicology studies, we will be developing manufacturing processes, and doing any final tweaks necessary on the formulation." - with no mention of combination tests.Then right at the end of the interview AR said "One of the things we will also be looking at will be how our drug inter-reacts with those existing drugs because I think there could be some really interesting possibilities there and just like cancer one drug alone often is not enough and you often need to have a cacktail of drugs so this is something we will be looking at in the future too."So his comment was quite vague and I guess he only had limited time.Does 'looking at in the future' mean a test, or just to review existing data, or reviewing the market potential for such a combination?Perhaps they will include some combined tests within the toxicology studies?Hopefully will be expanded on at some point.Just corrected a couple of errors and some **** censored the word ****tail.

Morning FFS - yes it was odd not to mention the combines tests carried out last year.
Earlier in the interview AR said "So the work we are going to do to make this phase 1 ready will be formal toxicology studies, we will be developing manufacturing processes, and doing any final tweaks necessary on the formulation." - with no mention of combination tests.
Then right at the end of the interview AR said "One of the things we will also be looking at will be how our drug inter-reacts with those existing drugs because I think there could be some really interesting possibilities there and just like cancer one drug alone often is not enough and you often need to have a ****tail of drugs so this is something we will be looking at in the future too."
So his comment was quite vague and I guess he only had limited time.
Does 'looking at in the future' mean a test, or just to review existing data, or reviewing the market potential for such a combination?
Perhaps they will include some combined tests within the toxicology studies?
Hopefully will be expanded on at some point.

I believe JH was involved in the recent 004 research and patent filing in a consultant role.
I guess that, dependent upon any other commitments, she could possibly be involved in the future in a similar manner, if required.
Certainly a benefit to have the continuity of her knowledge and experience rather than someone else.

AR stated that 'tranilast was limited to japan, Korea and China due to its solubility issues'.
I believe NXP002 will be okay worldwide.

Presumably tranilast will remain banned but NXP002 (or whatever its commercial name) will be different so not on the list as the solubility and better control of dose, especially when inhaled direct to the lungs, presumably overcomes the issues.
Presumably the bod do not see a problem in that respect.

I think interview extremely positive and encouraging on many fronts.
Not least because, unlike DG, I consider both AR and AB as very cautious and measured in their approach and comments, preferring to understate and with any potential usually full of cautious caveats. So to have such positive comments about 002 and how the bod view its potential is really good.

Tranilast limitation to japan/ Kore/ China due to its solubility issues.
Nuformix has resolved the solubility issue so opens up the use of NXP002 to worldwide use.
The bod are very confident about the potential for 002

Very positive.
Confirmed january for durability study and stated it wa sto look at duration of effect in the inflammatory model.
Taking 002 to phase 1 ready by end of 2022.
Stated that 'We will become very interesting to the industry' 'in a £2.5 billion market.

Soup - 'Even without any licensing deals the IP portfolio must surely be worth a lot more than the MCap.'
Nuformix market cap currently valued at £9m and we have:
• NXP001 oncology licensing deal agreed with Oxilio with stage payments and potential £2m royalties per year.
PLUS the following IP for out-licensing:
• NXP001 CINV available for out-licensing
• NXP002 patents for improved IPF treatment with latest successful research results
• NXP004 patents for £Billion a year oncology drug, offering 10 year patent extension and reduced side effects, and now talking to originator and competitors about out-licensing.
• NXP004 potential use in IPF – as mentioned in RNS’s.
The potential deal value of either 002 or 004 alone could be huge.
Certainly seems a crazy low value considering the IP the company has got.
Recent RNS's should have added value since they removed significant risks/ confirmed successful outcomes for 004 and 002.
With the one day wonder investors out the way we will hopefully see better/ larger investors buying into the potential here.

I think even the Taliban would think twice before dealing with someone as dodgy him.